Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Single-blind, Observational, Comparative, Prospective, 36-month, Longitudinal, Controlled Study to Assess Efficacy of Siponimod (Mayzent) on Microglia in Patients With Active Secondary Progressive Forms of Multiple Sclerosis

Next Previous
Trial Profile

Open-label, Single-blind, Observational, Comparative, Prospective, 36-month, Longitudinal, Controlled Study to Assess Efficacy of Siponimod (Mayzent) on Microglia in Patients With Active Secondary Progressive Forms of Multiple Sclerosis

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 21 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Siponimod (Primary) ; Ocrelizumab
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

Most Recent Events

  • 13 May 2025 Status changed from completed to discontinued.
  • 09 Aug 2023 Phase changed from phase 4 to phase 2/3
  • 09 Aug 2023 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top